Spinal muscular atrophy

Spinal muscular atrophy (SMA) affects the motor neurons – the nerve cells responsible for controlling movement of the skeletal muscles. Damage to or complete loss of motor neurons causes muscle wasting or atrophy and weakness. The weakness is usually more severe in the proximal muscles (close to the centre of the body) and usually worsens with age.

SMA is caused by defects in the SMN1 gene, which is responsible for making a protein called the survival motor neuron (SMN) protein. Various factors can affect the amount of SMN protein available and this in turn affects the severity of the disease, which has been classified into different types depending on the maximum functional ability the affected person reaches: individuals with type I never manage to sit independently; those with type II achieve the ability to sit up on their own but never manage to walk independently; type III patients achieve the ability to walk but may lose this ability later or require a wheelchair for longer distances.

Read more about SMA at the NIH Genetics Home Reference site here

Our research in SMA focuses on the epidemiology of the disease, as well as standards of care, data sharing and patient registries. SMA is at the forefront of therapy development in neuromuscular disease, and with new treatments being developed and approved, this background data is becoming essential for providing evidence to payers about the numbers of people benefiting from new therapies as well as determining long-term outcomes and access to therapies.

 

 

*Photo with the kind permission of Vitaliy Matyushenko, Children with Spinal Muscular Atrophy, Ukraine

 

Girl with SMA takes selfie with her brother

Relevant publications

Danko, V, Jüngert, J, Schuessler, S, Buehler, A, Klett, D, Federle, A et al.. Hybrid reflected-ultrasound computed tomography versus B-mode-ultrasound for muscle scoring in spinal muscular atrophy. J Neuroimaging. 2023. PMID:36627228

Pechmann, A, Behrens, M, Dörnbrack, K, Tassoni, A, Wenzel, F, Stein, S et al.. Improvements in Walking Distance during Nusinersen Treatment - A Prospective 3-year SMArtCARE Registry Study. J Neuromuscul Dis. 2023.10 (1)29-40 PMID:36565133

Landfeldt, E, Abner, S, Pechmann, A, Sejersen, T, McMillan, HJ, Lochmüller, H et al.. Caregiver Burden of Spinal Muscular Atrophy: A Systematic Review. Pharmacoeconomics. 2022. PMID:36515815

Karimzadeh, P, Najmabadi, H, Lochmuller, H, Babaee, M, Dehdahsi, S, Miryounesi, M et al.. Five patients with spinal muscular atrophy-progressive myoclonic epilepsy (SMA-PME): a novel pathogenic variant, treatment and review of the literature. Neuromuscul Disord. 2022.32 (10)806-810 PMID:36309462

Pechmann, A, Behrens, M, Dörnbrack, K, Tassoni, A, Wenzel, F, Stein, S et al.. Improved upper limb function in non-ambulant children with SMA type 2 and 3 during nusinersen treatment: a prospective 3-years SMArtCARE registry study. Orphanet J Rare Dis. 2022.17 (1)384 PMID:36274155

Jacquier, A, Risson, V, Simonet, T, Roussange, F, Lacoste, N, Ribault, S et al.. Severe congenital myasthenic syndromes caused by agrin mutations affecting secretion by motoneurons. Acta Neuropathol. 2022.144 (4)707-731 PMID:35948834

Pechmann, A, Behrens, M, Dörnbrack, K, Tassoni, A, Stein, S, Vogt, S et al.. Effect of nusinersen on motor, respiratory and bulbar function in early-onset spinal muscular atrophy. Brain. 2022. PMID:35857854

Schorling, DC, Kölbel, H, Hentschel, A, Pechmann, A, Meyer, N, Wirth, B et al.. Cathepsin D as biomarker in cerebrospinal fluid of nusinersen-treated patients with spinal muscular atrophy. Eur J Neurol. 2022.29 (7)2084-2096 PMID:35318785

Regensburger, AP, Wagner, AL, Danko, V, Jüngert, J, Federle, A, Klett, D et al.. Multispectral optoacoustic tomography for non-invasive disease phenotyping in pediatric spinal muscular atrophy patients. Photoacoustics. 2022.25 100315 PMID:34849338

Töpf, A, Pyle, A, Griffin, H, Matalonga, L, Schon, K, Solve-RD SNV-indel working group et al.. Exome reanalysis and proteomic profiling identified TRIP4 as a novel cause of cerebellar hypoplasia and spinal muscular atrophy (PCH1). Eur J Hum Genet. 2021.29 (9)1348-1353 PMID:34075209

See more on PubMed